{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:42:16Z","timestamp":1791906136793,"version":"4.3.4"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Retinal vein occlusion (RVO) is the second most common retinal vascular cause of vision loss after diabetic retinopathy and can lead to substantial visual impairment due to retinal ischemia, hemorrhage, vascular leakage, and macular edema. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is currently the first-line treatment for RVO-associated macular edema, with its efficacy confirmed by numerous large-scale randomized controlled trials. However, VEGF is not the only pathological driver in RVO. Angiopoietin-2 (Ang-2) has emerged as a key factor that contributes to disease progression by destabilizing the vascular endothelium through disruption of the Tie2 signaling pathway, increasing vascular permeability, and intensifying inflammation. Faricimab is a bispecific monoclonal antibody that targets both VEGF-A and Ang-2, providing a dual mechanism of action that includes anti-permeability, anti-angiogenic, and anti-inflammatory effects. In both the BALATON and COMINO trials, patients with RVO achieved mean best-corrected visual acuity (BCVA) improvements of approximately +17 to +19 letters, along with central subfield thickness (CST) reductions exceeding 300\u00a0\u03bcm in both treatment arms after Faricimab treatment. Compared to traditional single-target anti-VEGF agents, Faricimab has demonstrated non-inferior or even superior outcomes in visual and anatomical improvements, while also offering extended dosing intervals and reduced treatment burden. Nevertheless, its safety profile positions it mid-range among anti-VEGF therapies. This review outlines the molecular rationale, key clinical trial data, comparative efficacy and safety, and current challenges and future directions for Faricimab in RVO management, aiming to inform its clinical application in RVO and broader retinal vascular disorders.<\/jats:p>","DOI":"10.3389\/fphar.2025.1646806","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:26:32Z","timestamp":1760419592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Faricimab for retinal vein occlusion: a review of current evidence and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Yongjie","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-Engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s00417-024-06485-y","article-title":"Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration","volume":"262","author":"Aljundi","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/medicina57101017","article-title":"Effects of antithrombotic agents on ophthalmological outcomes, cardiovascular risk, and mortality in hypertensive patients with retinal vein occlusion: an exploratory retrospective study","volume":"57","author":"Bertoli","year":"2021","journal-title":"Med. Kaunas."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e20240277","DOI":"10.5935\/0004-2749.2024-0277","article-title":"Real-world safety and efficacy of Anti-VEGF treatment in Brazil","volume":"88","author":"Bulla","year":"2025","journal-title":"Arq. Bras. Oftalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.18240\/ijo.2021.06.20","article-title":"Intraocular pressure modifications in patients with acute central\/hemicentral retinal vein occlusions","volume":"14","author":"C\u0103lug\u0103ru","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front. Cell Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41433-024-02936-2","article-title":"Infographic: study design of the BALATON and COMINO phase 3 randomised trials of faricimab in patients with retinal vein occlusion","volume":"38","author":"Chang","year":"2024","journal-title":"Eye (Lond)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: a systematic review and network meta-analysis of randomized controlled trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.3390\/jcm13154533","article-title":"Evaluation of anatomical and tomographic biomarkers as predictive visual acuity factors in eyes with retinal vein occlusion treated with dexamethasone implant","volume":"13","author":"Covello","year":"2024","journal-title":"J. Clin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B12","unstructured":"Indication: for the treatment of macular edema secondary to retinal vein occlusion: reimbursement recommendation\n          \n          \n          2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"110436","DOI":"10.1016\/j.exer.2025.110436","article-title":"Progress in single-cell sequencing of retinal vein occlusion or ischemic hypoxic retinopathy","volume":"257","author":"Feng","year":"2025","journal-title":"Exp. Eye Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14728222.2022.2036121","article-title":"The emerging role of the angiopoietin-tie pathway as therapeutic target for treating retinal diseases","volume":"26","author":"Ferro Desideri","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"B15","unstructured":"Genentech: our pipeline\n          \n          \n          2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"B17","first-page":"128","article-title":"Branch retinal vein occlusion","volume":"20","author":"Hamid","year":"2008","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","article-title":"BALATON and COMINO: phase III randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale","volume":"3","author":"Hattenbach","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"key":"B21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","article-title":"Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease","volume":"28","author":"Hussain","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1567202617999200831151118","article-title":"Creation of retinal vein occlusion model in cynomolgus monkeys and determination of its pathological features","volume":"18","author":"Inagaki","year":"2021","journal-title":"Curr. Neurovasc Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22608\/APO.2017442","article-title":"Retinal vein occlusion review","volume":"7","author":"Ip","year":"2018","journal-title":"Asia Pac J. Ophthalmol. (Phila)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/APO.0000000000000634","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with diabetic macular edema: 1-year subgroup analysis of the phase III YOSEMITE and RHINE trials","volume":"12","author":"Ishida","year":"2023","journal-title":"Asia Pac J. Ophthalmol. (Phila)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e41752","DOI":"10.1097\/MD.0000000000041752","article-title":"Insights into modifiable risk factors of retinal vascular occlusion: a Mendelian randomization study","volume":"104","author":"Jiang","year":"2025","journal-title":"Med. Baltim."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as potential targets in management of retinal disease","volume":"15","author":"Khanani","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1160\/TH09-05-0331","article-title":"Coagulation disorders and the risk of retinal vein occlusion","volume":"103","author":"Kuhli-Hattenbach","year":"2010","journal-title":"Thromb. Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"176691","DOI":"10.1016\/j.ejphar.2024.176691","article-title":"The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice","volume":"976","author":"Kuriyama","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye (Lond)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/jcm13133950","article-title":"Retinal vein occlusion-background knowledge and foreground knowledge Prospects-A review","volume":"13","author":"Lendzioszek","year":"2024","journal-title":"J. Clin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e36370","DOI":"10.1097\/MD.0000000000036370","article-title":"Comparative efficacy and safety of faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li","year":"2023","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/WNO.0000000000001813","article-title":"Literature commentary","volume":"43","year":"2023","journal-title":"J. Neuroophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40360-025-00902-6","article-title":"Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER","volume":"26","author":"Liu","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/OPTH.S236637","article-title":"The evolving treatment of diabetic retinopathy","volume":"14","author":"Mansour","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000541662","article-title":"Efficacy and safety of intravitreal faricimab in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a meta-analysis","volume":"247","author":"Nichani","year":"2024","journal-title":"Ophthalmologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/OPTH.S499960","article-title":"Preoperative retinal detachment variables causing macular detachment","volume":"19","author":"Nishimura","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e27628","DOI":"10.1097\/MD.0000000000027628","article-title":"Hypertension as a risk factor for retinal vein occlusion in menopausal women: a nationwide Korean population-based study","volume":"100","author":"Oh","year":"2021","journal-title":"Med. Baltim."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des. Devel Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol. Retina"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10571-024-01525-x","article-title":"Glucocorticoid-dependent retinal degeneration and vision impairment in mice susceptible to prenatal stress-induced behavioral abnormalities","volume":"45","author":"Ryu","year":"2024","journal-title":"Cell Mol. Neurobiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4103\/IJO.IJO_1700_24","article-title":"Risk factors and incidence of macular edema in eyes with retinal vein occlusion after uneventful cataract surgery: the MEVO study","volume":"73","author":"Sen","year":"2025","journal-title":"Indian J. Ophthalmol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14712598.2023.2247987","article-title":"The evolving therapeutic landscape of diabetic retinopathy","volume":"23","author":"Shughoury","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"102188","DOI":"10.1016\/j.ajoc.2024.102188","article-title":"Retinal racemose hemangioma presenting with a chorioretinal anastomosis","volume":"36","author":"Soetikno","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"910600","DOI":"10.3389\/fmed.2022.910600","article-title":"Review: the development of risk factors and cytokines in retinal vein occlusion","volume":"9","author":"Tang","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41433-022-01957-z","article-title":"Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration","volume":"37","author":"Teo","year":"2023","journal-title":"Eye (Lond)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mvr.2010.05.011","article-title":"Improved assessment of laser-induced choroidal neovascularization","volume":"80","author":"Toma","year":"2010","journal-title":"Microvasc. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1159\/000540194","article-title":"Efficacy and durability of faricimab in na\u00efve eyes with neovascular age-related macular degeneration","volume":"67","author":"Toto","year":"2024","journal-title":"Ophthalmic Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jtha.2022.10.003","article-title":"Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis","volume":"21","author":"Valeriani","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/aos.13909","article-title":"Glucocorticoids exert differential effects on the endothelium in an in vitro model of the blood-retinal barrier","volume":"97","author":"van der Wijk","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e001967","DOI":"10.1136\/bmjophth-2024-001967","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong","year":"2025","journal-title":"BMJ Open Ophthalmol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1445-5994.2008.01720.x","article-title":"Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management","volume":"38","author":"Yau","year":"2008","journal-title":"Intern Med. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"886","DOI":"10.18240\/ijo.2020.06.05","article-title":"Intravitreal injection of resveratrol inhibits laser-induced murine choroidal neovascularization","volume":"13","author":"Zhang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13287-021-02349-y","article-title":"DPSCs treated by TGF-\u03b21 regulate angiogenic sprouting of three-dimensionally co-cultured HUVECs and DPSCs through VEGF-Ang-Tie2 signaling","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:26:36Z","timestamp":1760419596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":61,"alternative-id":["10.3389\/fphar.2025.1646806"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1646806","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1646806"}}